1. Chronic Venous Disease during Pregnancy Is Related to Inflammation of the Umbilical Cord: Role of Allograft Inflammatory Factor 1 (AIF-1) and Interleukins 10 (IL-10), IL-12 and IL-18
- Author
-
Ortega, Lara Sánchez-Trujillo, Oscar Fraile-Martinez, Cielo García-Montero, Luis M. García-Puente, Luis G. Guijarro, Diego De Leon-Oliva, Diego Liviu Boaru, David Gardón-Alburquerque, María del Val Toledo Lobo, Mar Royuela, Ignacio García-Tuñón, Antonio Rios-Parra, Juan A. De León-Luis, Coral Bravo, Melchor Álvarez-Mon, Julia Bujan, Miguel A. Saez, Natalio García-Honduvilla, and Miguel A.
- Subjects
chronic venous disease (CVD) ,pregnancy ,umbilical cord ,inflammation ,Allograft inflammatory factor 1 (AIF-1) ,Interleukin 10 (IL-10) ,IL-12A ,IL-18 - Abstract
Chronic venous disease (CVD) is a common condition that affects the veins in the lower limbs, resulting in a variety of symptoms, such as swelling, pain, and varicose veins (VVs). The plenty hormonal, hemodynamic and mechanical changes occurred in pregnancy make women especially vulnerable to suffer from this condition in this period. Previous works have identified that CVD is associated with an increased inflammatory milieu and significant damage in maternofetal tissues, such as the umbilical cord. However, the inflammatory status of this structure in these patients has not been studied yet. Thus, the aim of the present study was to examine gene and protein expression of a set of inflammatory markers—Allograft inflammatory factor 1 (AIF-1), the proinflammatory cytokines interleukin 12A (IL-12A) and IL-18 and the anti-inflammatory product IL-10—in the umbilical cord of women with CVD during pregnancy (N = 62) and healthy pregnant women (HC; N = 52) by the use of real time qPCR and immunohistochemistry (IHC). Our results demonstrate that the umbilical cord tissue from CVD women exhibit an increased expression of AIF-1, IL-12A and IL-18 along with a decrease in IL-10. Therefore, our study suggests an inflammatory status of this structure related to CVD. Further studies should be conducted to evaluate the expression of other inflammatory markers, as well as to analyze the maternofetal impact of these findings.
- Published
- 2023
- Full Text
- View/download PDF